WHO ICTRP trial
The effective dose of remimazolam combined with different doses of olanzapine…
ChiCTR2400094020 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400094020 |
|---|---|
| Public title | The effective dose of remimazolam combined with different doses of olanzapine fumarate in hysteroscopic examination surgery. |
| Scientific title | The effective dose of remimazolam combined with different doses of olanzapine fumarate in hysteroscopic examination surgery. |
| Primary sponsor | Affiliated Shunde Hospital of Jinan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Interventions | Remimazolam +0.02mg/kg oxalidine fumarate group:0.02mg/kg oliceridine+ remimazolam;Remimazolam +0.025mg/kg oxalidine fumarate group:0.025mg/kg oliceridine+ remimazolam |
| Registration date | Dec 16, 2024 |
| Target size | Remimazolam +0.02mg/kg oxalidine fumarate group:35;Remimazolam +0.025mg/kg… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: